Изучение возможности лечения лимфосаркомы Плисса химико-биологическим аддуктом 1,1-бис-[5-бромопиридин-2’,4’-дион-1’-ил]-2-бромо-2’-хлороэтилена и бактериального лектина

O. V. Welchinska

doi:10.14739/2310-1210.2015.2.42048

Authors

O. V. Welchinska

DOI:

https://doi.org/10.14739/2310-1210.2015.2.42048

Keywords:

5-Fluorouracil, Antineoplastic Antimetabolites, Lectins, Lymphatic Sarcoma

Abstract

Aim. Study of the pyrimidine metabolism antimetabolites that can be preformed compounds in the link of biosynthetic processes and can brake tumour’s growth is a more successful, perspective finding direction of new antitumor medications. New original chemical-biological adduct was studied as potential antitumor agent.

Methods and results. It was obtained on the base of 1,1-bis-[5-bromopyrimidine-2’,4’-diono-1’-il]-2-bromo-2’-chloroethylene and antitumour bacterial lectin from Bacillus polymyxa. It was found that new chemical-biological adduct of bis-derivative of pyrimidine and bacterial lectin has little toxic preparation (LD₅₀=635 mg/kg) and demonstrates considerable antitumour effect upon to 65.5% on Pliss Limphosarcoma tumour.

Conclusion. It confirms that new chemical-biological adduct is perspective for the future investigation as substance with a little toxicity and high antitumour activity on the Pliss Limphosarcoma.

References

Adjei, A. A. (1999). Review of pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. Clinical Pharmacology, 48, 265–277. doi: 10.1046/j.1365-2125.1999.00010.x.
Anderson, N., & Lokich, J. (1992). Controversial issues in 5-fluorouracil infusion use. Dose intensity, treatment duration, and cost comparisons. Cancer, 70, 998–1002.
Anttila, M. I., Sotaniemi, E. A. & Kairaluoma, M. I. (1983). Pharmacokinetics of ftorafur after intravenous and oral administration. Cancer Chemotherapy and Pharmacology, 10, 150–153.
Baba, H., Kohnoe, S., Endo, K., Ikeda, Y., Toh Y., Nakashima, H., & Okamura, T. (2000). State of the treatment for gastrointestinal cancer. Gan To Kagaku Ryoho, 27, 1233–1246.
Kleckij, M. E., Cupak, E. B. & Nazarov, D. A. (2002). Struktura i reakcionnaya sposobnost` proizvodnykh uracila [Structure and reactive ability of derivatives of uracile]. Himiya geterociklicheskikh soedinenij, 8, 1106–1108. [in Russian].
Noordhuis, P., Holwerda, U., Van der Wilt, C. L., Van Groeningen, C. J., Smid, K., Meijer, S., et al. (2004). 5-fluorouracil incorporation info RNA and DNA in relation to thymidilate synthetase inhibition human colorectal cancer. Annals. of oncol., 15, 1025–1032.
Longley, D. B., & Harkin, D. P. (2004). Mechanisms of action of 5-fluorouracil. Nature Rev. Cancer, 4, 230–238.
Longey, D. B., Harkin, D. P. & Jonson P. G. (2003). 5-fluorouracil - mechanisms of action and clinical strategies. Nature Reviews. Cancer, 3, 330–338. doi:10.1038/nrc1074.
(2006). Klinitcni protokoly spetsializovanoi dopomogy khvorym na zloiakisni novoutvorennia. Rekomendatsii schodo standartnoi medychnoi dopomogy khvorym na zloiakisni novoutvorennia [Clinical protocols of special helping to the patients with malignant new formations. Reccomendations for standart medical helping to the patients with malignant new formations]. Kyiv: Polium. [in Ukrainian].
Perevodchikova, N. I. (Ed.). (2005). Rukovodstvo po khimioterapiy opukholevih zabolevaniy [Instruction for chemical therapy of cancers’s illnesses]. Moscow: Practical medicine. [in Russian].
Karatsuba, T. A., Sharykina, N. I. & Scheglov, V.I. (2002). Suchasni mozhlyvosti vplyvu farmakoterapii na rist ta protsesy metastazuvannia zloiakisnykh pukhlyn [Modern possibilities of the action of pharmacotherapy on the grows and processes of metastasis of the cancers]. Liki, 1(3–4), 3–6. [in Ukrainian].
Kudriavtseva, I. H., & Sharykina, N. I. (2004). Suchasnyi stan poshuku i vyvchennia FAR z protypukhlynnoiu diieiu sered pokhidnykh kysloty fosforu [Modern situation of finding and learning of PhAS with antitumour action besides derivatives of phosphorus’s acids]. Liki, 1–2, 31–40. [in Ukrainian].
Kudriavtseva, I. H., & Sharykina, N. I. (2004). Suchasnyi stan poshuku i vyvchennia FAR z protypukhlynnoiu diieiu sered pokhidnykh kysloty fosforu [Modern situation of finding and learning of PhAS with antitumour action besides derivatives of phosphorus’s acids]. Liki, 3–4, 40–52. [in Ukrainian].
Prozorovskij, V. B., Prozorovskij, V. P. & Demchenko, V. М. (1978). E`kspress-metod opredeleniya srednej e`ffektivnosti dozy i ego oshibka [Express-method of middle effective dose determination and its mistake]. Farmakologiya i toksikologiya, 41(4), 407–509. [in Russian].
Kovalenko, E`. A., Nagornaya, S. S. & Get`iman, E. N. (2001). Poisk producentov lektinov sredi nekotorykh vidov drozhzhej [Finding of the lectin’s producents besides of some types of yeasts]. Mikrobiolohichnyi zhurnal, 63(5), 44–48. [in Ukrainian].
Blokhin, N. N., & Perevodchikova, N. I. (1984). Khimioterapiya opukholevykh zabolevanij [Chemical therapy of the cancer’s illnesses]. Moscow: Medicine. [in Russian].
Sophjina, Z. P., Syrkin, A. B., Goldin, A., & Klyajn, A. (Eds.) (1979). E`ksperimentalnaya ocenka protivoopukholevykh preparatov v SSSR i SShA [The experimental value of the antitumour drugs in USSR and USA]. Moscow: Medicine. [in Russian].